Home

Bristol Myers Squibb Co. (BMY)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Bristol Myers Squibb Co. (BMY)

Go deeper and ask any question about BMY

Company Performance

Current Price

as of Sep 13, 2024

$49.13

P/E Ratio

N/A

Market Cap

$99.61B

Description

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Metrics

Overview

  • HQPrinceton, NJ
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerBMY
  • Price$49.13+1.84%

Trading Information

  • Market Cap$99.61B
  • Float99.92%
  • Average Daily Volume (1m)8,800,454
  • Average Daily Volume (3m)14,531,733
  • EPS-$3.25

Company

  • Revenue$46.51B
  • Rev Growth (1yr)8.69%
  • Net Income$1.68B
  • Gross Margin55.74%
  • EBITDA Margin42.17%
  • EBITDA$5.15B
  • EV$131.67B
  • EV/Revenue2.83
  • P/EN/A
  • P/S2.14
Documents
SEC Filings
8-K (2024-07-26)
8-K (2024-06-18)
8-K (2024-05-09)
8-K (2024-04-25)
8-K (2024-03-18)
8-K (2024-02-22)
8-K (2024-02-15)
8-K (2024-02-14)
8-K (2024-02-02)
8-K (2024-01-08)
8-K (2023-12-22)
8-K (2023-11-13)
8-K (2023-10-26)
8-K (2023-08-10)
8-K (2023-07-27)
8-K (2023-05-04)
8-K (2023-04-27)
8-K (2023-04-26)
8-K (2023-02-28)
8-K (2023-02-02)
8-K (2023-01-31)
8-K (2023-01-09)
10-Q (2024-07-26)
10-Q (2024-04-25)
10-Q (2023-10-26)
10-Q (2023-07-27)
10-Q (2023-04-27)
10-K (2024-02-13)
10-K (2023-02-14)
Factset Street Account
StreetAccount Metrics Recap - Bristol Myers Squibb Q3 Earnings ($56.61, 0.00) (2023-10-26T11:04:31Z)
StreetAccount Earnings Call Q&A Summary: Bristol Myers Squibb Q3 ($56.61, 0.00) (2023-10-26T13:43:31Z)
StreetAccount Consensus Metrics Preview - Bristol Myers Squibb Q3 Earnings ($56.46, 0.00) (2023-10-23T16:17:34Z)
FDA approves sBLA for Opdivo as adjuvant treatment for melanoma ($56.47, 0.00) (2023-10-13T22:12:45Z)
EU's CHMP adopted a positive opinion recommending the granting of a marketing authorisation for Naveruclif (2023-11-10T12:43:35Z)
EMA valicates Bristol Myers Squibb application for Opdivo (nivolumab) in combination with cisplatin-based chemotherapy for the first-line treatment of adult patients with Unresectable or Metastatic Urothelial Carcinoma ($51.02, 0.00) (2023-10-30T11:00:42Z)
Bristol Myers Squibb upgraded to hold from reduce at HSBC ($52.97, 0.00) (2023-10-27T10:21:56Z)
Bristol Myers Squibb to present new data at the American Heart Association Scientific Sessions 2023 ($52.82, 0.00) (2023-11-06T12:04:44Z)
Bristol Myers Squibb reports Q3 non-GAAP EPS $2.00 vs FactSet $1.76 [20 est, $1.67-1.87] ($56.61, 0.00) (2023-10-26T11:03:41Z)
Bristol Myers Squibb downgraded to neutral from overweight at Cantor Fitzgerald ($50.52, 0.00) (2023-11-15T11:12:45Z)
Bristol Myers Squibb downgraded to market perform from outperform at William Blair ($52.97, 0.00) (2023-10-27T09:09:22Z)
Bristol Myers Squibb downgraded to hold from outperform at Daiwa ($51.28, 0.00) (2023-11-02T12:17:13Z)
Bristol Myers Squibb announces three-year follow-up results from exploratory analyses of the Phase 3 CheckMate -816 trial ($57.29, +0.11) (2023-10-17T19:54:36Z)
Bristol Myers Squibb announces presentation of research across hematology and cell therapy portfolio and pipeline at ASH 2023 ($50.99, -0.29) (2023-11-02T15:40:30Z)
Bristol Myers Squibb announces highlighted data to be presented at ESMO 2023 ($56.65, 0.00) (2023-10-12T11:22:09Z)
Bristol Myers Squibb announces first presentation of results from the Phase 3 CheckMate -901 trial ($57.30, +0.13) (2023-10-17T19:52:13Z)
Bristol Myers Squibb announces FDA Breakthrough Therapy Designation for BMS-986278 ($56.00, 0.00) (2023-10-24T11:01:46Z)
Bristol Myers Squibb announces FDA accepts for priority review application for Breyanzi (lisocabtagene maraleucel) for relapsed or refractory CLL or SLL ($51.79, -0.64) (2023-11-09T15:16:12Z)
Bristol Myers Squibb announced the first disclosure of data from the Phase 3 CheckMate -77T trial evaluating the perioperative regimen of neoadjuvant Opdivo (nivolumab) with chemotherapy ($57.33, +0.16) (2023-10-17T19:28:06Z)
Wikipedia
Bristol_Myers_Squibb_Co.
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-10-26)
Earnings Report (2023-07-27)
Factset
Factset Business Description